hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06375564 id: XMYY-2020KY067-05 briefTitle: Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression overallStatus: RECRUITING date: 2024-05-01 date: 2025-12-30 date: 2026-12-30 date: 2024-04-19 date: 2024-04-23 name: The First Affiliated Hospital of Xiamen University class: OTHER briefSummary: This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD. conditions: Refractory Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: 177Lu-AB-3PRGD2 radioligand therapy measure: Objective response rate (ORR) measure: Incidence of treatment-related adverse events (safety and tolerability) sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Xiamen University status: RECRUITING city: Xiamen state: Fujian zip: 361003 country: China name: Haojun Chen role: CONTACT phone: +8618659285282 email: leochen0821@foxmail.com name: Hao Fu, MD, PhD role: CONTACT phone: +8615959230059 email: fuhaonuclear@163.com name: Haojun Chen, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Hao Fu, MD, PhD role: SUB_INVESTIGATOR lat: 24.47979 lon: 118.08187 hasResults: False
nctId: NCT06375538 id: B2022-527 briefTitle: Ultrasound Evaluations of Diaphragm and Intercostal Muscle to Predict the Failure of High-Flow Nasal Cannula Therapy overallStatus: RECRUITING date: 2022-10-21 date: 2025-08-31 date: 2025-12-31 date: 2024-04-19 date: 2024-04-19 name: Shanghai Zhongshan Hospital class: OTHER briefSummary: The study aims to predict the failure of High-flow Nasal Cannula oxygenation therapy by ultrasound evaluation of diaphragm and intercostal muscle contraction during the first 24 hours. conditions: High-flow Nasal Cannula conditions: Ultrasound Evaluation conditions: Diaphragm and Intercostal Muscle studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Ultrasound evaluation of diaphragm measure: Ultrasound evaluation of intercostal muscle movement index measure: The patient's condition deteriorated and required noninvasive or intubated invasive mechanical ventilation. measure: ICU stay measure: Hospital stay measure: all cause mortality measure: Oxygen saturation measure: respiratory rate measure: oxygen concentration measure: flow velocity of HFNC measure: VT measure: duration on HFNC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Zhongshan Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Wei Wu role: CONTACT phone: 13817976707 email: wu.wei1@zs-hospital.sh.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06375525 id: SHEBA-15-2635-SMC briefTitle: Clinical Trial: The Efficacy of Janssen's Icon Application (App) in Improving Adherence to Treatment With Stimulant Medications in Children With Attention Deficit/Hyperactivity Disorder acronym: App ADHD overallStatus: COMPLETED date: 2015-11 date: 2017-08 date: 2017-08 date: 2024-04-19 date: 2024-04-19 name: Prof. Doron Gothelf MD class: OTHER_GOV briefSummary: The overarching aim of the study is to assess the efficacy of Janssen's icon Application (App), a digital tool designed to improve adherence to medication treatment in children with ADHD.
2. Adherent patients will show greater improvement of ADHD symptoms and related dysfunction. conditions: Children Aged 6-18 Years With the Diagnosis of ADHD studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 39 type: ACTUAL name: Janssen's icon Application (App) measure: Attention Module of the Kiddie-SADS questionniare measure: MINI-KID measure: ADHD-Rating Scale Questionnaire (ADHD-RS) measure: Clinical Global Impression Scale (CGI) measure: the Barkley Side Effects Rating Scale measure: Drug accountability by reviewing the completed medication logs sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: ADHD Medical Clinic, Child and Adolescent Psychiatry Unit, Sheba Medical Center city: Ramat-Gan country: Israel lat: 32.08227 lon: 34.81065 hasResults: False
nctId: NCT06375512 id: IN001001 briefTitle: A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-12 date: 2026-06 date: 2024-04-19 date: 2024-04-19 name: Shenzhen Shenxin Biotechnology Co., Ltd class: INDUSTRY briefSummary: The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age conditions: Herpes Zoster studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: HZ Vaccine (IN001) name: Placebo name: Shingrix measure: Percentage of Participants Reporting Solicited Local Reactions measure: Percentage of Participants Reporting Solicited Systemic Reactions measure: Percentage of Participants With Unsolicited Adverse Events (AEs) measure: Percentage of Participants With Any Medically Attended AEs (MAAEs) measure: Percentage of Participants With Any Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), AEs Leading to Vaccine Discontinuation, and AEs Leading to Study Withdrawal measure: Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) measure: Change from Baseline in Geometric Mean Fold Rise (GMFR) of Anti-gE Antibodies as Measured by ELISA measure: Proportion of Participants with Vaccine Response in Anti-gE Antibodies as Measured by ELISA measure: Geometric Mean Titer (GMT) of Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay measure: Change from Baseline in GMFR of Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay measure: Proportion of Participants with Vaccine Response in Anti-VZV Neutralizing Antibodies as Measured by Neutralization Assay measure: gE-specific T Cell Response (IFN-γ and IL-4 Secreting T Cells) as Measured by Enzyme-Linked Immunospot (ELISpot) measure: Frequencies of gE-specific CD4+ and CD8+ T Cells Expressing Activation Markers (i.e., IFN-γ, IL-2, TNFα, CD40L) as Measured by Intracellular Cytokine Staining (ICS) sex: ALL minimumAge: 50 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375499 id: LT2769-004 briefTitle: Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2025-04-28 date: 2025-04-28 date: 2024-04-19 date: 2024-04-19 name: Laboratoires Thea class: INDUSTRY briefSummary: The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36 visit.
The investigation is defined as a post-market stage. The clinical investigation design is confirmatory. conditions: Dry Eye Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 74 type: ESTIMATED name: T2769 name: Hylo-Forte® measure: To demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of total ocular surface staining (Oxford score). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375486 id: AK112-IIT-TianjinCIH-LHK briefTitle: Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. overallStatus: RECRUITING date: 2024-03-14 date: 2025-03-14 date: 2026-06-15 date: 2024-04-19 date: 2024-04-19 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China. The primary objective is to evaluate the safety and efficacy of AK112 (a dual-specific antibody against PD-1/VEGF) in combination with hepatic arterial infusion chemotherapy (HAIC) for the treatment of unresectable hepatocellular carcinoma.
All enrolled subjects will receive AK112 (20mg/kg Q3W) combined with HAIC (utilizing the FOLFOX chemotherapy regimen) until the investigator determines no further clinical benefit (based on RECIST v1.1 imaging evaluation and clinical assessment), intolerable toxicity, completion of 24 months of treatment, or meeting other criteria for treatment discontinuation as outlined in the protocol, whichever occurs first. conditions: Hepatocellular Carcinoma Non-resectable conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） measure: Overall response rate (ORR) measure: Progress Free Survival （PFS） measure: Overall survival (OS) measure: Adverse Events（AEs） sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Cancer Hospital Airport Hospital status: RECRUITING city: Tianjin state: Tianjin zip: 300308 country: China name: Huikai Li, Doctor role: CONTACT phone: 18622228639 email: tjchlhk@126.com name: Yang Liu, MD role: CONTACT phone: 17694950696 email: tjchlhk@126.com lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06375473 id: MA-PC-RWS-011 briefTitle: Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients acronym: MA-PC-RWS-011 overallStatus: NOT_YET_RECRUITING date: 2024-04-19 date: 2027-04-19 date: 2027-04-19 date: 2024-04-19 date: 2024-04-19 name: Peking Union Medical College Hospital class: OTHER briefSummary: This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen. conditions: Pancreatic Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3000 type: ESTIMATED name: Irinotecan liposome II combination therapy regimen measure: rwTEAE measure: OS measure: PFS measure: ORR measure: TTP measure: DCR sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital city: Beijing state: Beijing zip: 100730 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06375460 id: STUDY24020141 id: 1R01DK137803-01A1 type: OTHER_GRANT domain: NIDDK briefTitle: Real-time Engagement for Learning to Effectively Control Type 2 Diabetes acronym: REFLECT2D overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2028-06-01 date: 2029-06-30 date: 2024-04-19 date: 2024-04-19 name: University of Pittsburgh class: OTHER name: Dartmouth College name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) name: University of Michigan name: San Diego State University briefSummary: This is a clinical trial that includes a run-in period, a 90 day micro-randomized trial, and a 90-day observational period. The goal of this study is to evaluate whether providing paired real time glycemic and health behavior data in a smartphone app leads to better glycemic control among adolescents and young adults with T2D. Glycemic control will be monitored using Continuous Glucose Monitors (CGM), and health behavior data will be collected via a Fitbit activity tracker and a research app (Healthmine). Participants will be prompted to view and reflect on glycemic trends and health behavior data (Fitbit data, logging of diet and medication adherence) during the 90-day micro-randomized trial period, then observed for ongoing use of the Healthmine app and engagement with CGM in the following 90-day observation period. conditions: Diabetes Mellitus, Type 2 conditions: Lifestyle conditions: Hyperglycemia conditions: Physical Inactivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Subjects will wear a continuous glucose monitor and activity watch for study duration. Subjects will be micro-randomized once daily for 90 days to receive app prompts regarding nutrition or physical activity. primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Focused App Prompt name: No App Prompt measure: Glucose time above 180mg/dL measure: Mean daily glucose measure: Maximum daily glucose measure: Minimum daily glucose measure: Glucose coefficient of variability measure: Mean amplitude of glycemic excursions measure: Hemoglobin A1c measure: Fasting glucose measure: Objective physical activity (step count) measure: Objective physical activity (moderate-vigorous physical activity) measure: Self-reported physical activity measure: Diet quality measure: Capability measure: Healthmine app use measure: Continuous glucose monitor use use measure: Motivation to engage in diabetes self-management measure: Body Mass Index (BMI) measure: Diabetes distress measure: Diabetes family support and conflict sex: ALL minimumAge: 16 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT facility: Children's Hospital of Pittsburgh city: Pittsburgh state: Pennsylvania zip: 15224 country: United States lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06375434 id: 20240101-01 briefTitle: Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer acronym: GMRSC-LARC overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-08-15 date: 2024-08-31 date: 2024-04-19 date: 2024-04-19 name: Jing-kun Liu class: OTHER briefSummary: The purpose of this process is to clarify the characteristics of gut microbiota changes in patients with locally advanced rectal cancer undergoing preoperative neoadjuvant treatment, and to identify key bacterial species closely related to sensitivity to radiotherapy. This aims to elucidate the mechanism linking gut microbiome dysbiosis with radiotherapy sensitivity, thereby providing new combined treatment strategies to enhance the efficacy of radiotherapy. conditions: Locally Advanced Rectal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: No intervention measure: Diameter of tumor measure: Change in Gut Microbiota Composition measure: Change in Plasma metabolites measure: Five-year survival rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375421 id: GR018280 briefTitle: Pilot and Feasibility of MEMI for Chronic Traumatic Brain Injury overallStatus: ENROLLING_BY_INVITATION date: 2024-04-03 date: 2024-12-31 date: 2024-12-31 date: 2024-04-19 date: 2024-04-19 name: Vanderbilt University Medical Center class: OTHER briefSummary: This is a pilot and feasibility study for a mobile phone-delivered intervention for memory, called MEMI (memory ecological momentary intervention), that was designed to support adults with chronic traumatic brain injury with their memory. The goal of the study is to examine the feasibility and acceptability of MEMI and to assess preliminary efficacy as to whether technology-delivered spaced memory retrieval opportunities improve memory in people with and without a history of chronic traumatic brain injury. conditions: Traumatic Brain Injury studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The order of conditions and the order of word list presentation will be counterbalanced. The order of condition/word list combination will be pre-determined, and participants will be assigned to the next available combination based on when they join the study (i.e., a counterbalanced within-person crossover design). primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval name: Blocked Retrieval measure: Acceptability measure: Feasibility (Engagement) measure: Free Recall of Word Forms measure: Cued Recall of Word Forms measure: Cued Recall of Word Meanings measure: Number of Spatial Contexts sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Vanderbilt University Medical Center city: Nashville state: Tennessee zip: 37203 country: United States lat: 36.16589 lon: -86.78444 hasResults: False
nctId: NCT06375408 id: KS2022212 briefTitle: Transcranial Alternating Current Stimulation Prevents Delirium in Patients With Subarachnoid Hemorrhage acronym: TACS overallStatus: RECRUITING date: 2024-03-24 date: 2026-02-24 date: 2026-03-24 date: 2024-04-19 date: 2024-04-19 name: Xuanwu Hospital, Beijing class: OTHER briefSummary: The goal of this clinical trial is to learn about using the latest transcranial alternating current stimulation (tACS) to reduce the incidence of delirium in patients with subarachnoid hemorrhage. The main question it aims to answer is:
Participants will treated with real tACS or sham tACS. Researchers will mainly compare the two groups to see if patients' delirium will reduce by using tACS. conditions: Subarachnoid Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: The random number table method was used for randomization, and the envelope method was used for randomization. The random serial number was stored in an airtight envelope, an envelope was opened when a patient was admitted. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 74 type: ESTIMATED name: Real transcranial alternating electrical stimulation name: Sham transcranial alternating electrical stimulation measure: Incidence of delirium measure: Sleep quality score measure: Anxiety score measure: Duration of delirium measure: Cognitive function score sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xuanwu Hospital Capital Medical University status: RECRUITING city: Beijing state: Beijing zip: 100053 country: China name: Jun Wang role: CONTACT phone: 18612583695 email: wangj229@126.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06375395 id: Memory Updating Tasks briefTitle: Boosting The Intervention Effect of Negative Memory Through tACS Stimulation overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-12-15 date: 2024-12-31 date: 2024-04-19 date: 2024-04-19 name: Xuanwu Hospital, Beijing class: OTHER name: Beijing Normal University briefSummary: The objectives of this study include: 1) investigating the impact of negative memory substitution on an individual's other intellectual memories (i.e., neutral memories) and the underlying neurocognitive mechanisms; 2) investigating the memory enhancement effect resulting from retrieval practice associated with memory substitution intervention along with an examination of the neurocognitive mechanisms responsible for this enhancement. conditions: Seizures studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Active tACS Device name: Sham tACS Device measure: Negative memory retention measure: The negative emotional intensity of negative memory measure: The retention of associated neutral memories as assesses by the proportions of responses of correctly choosing picture category of B picture (A-Bneu) in last A-B paired associate memory test measure: The negative emotional intensity of neutral memory sex: ALL minimumAge: 14 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06375382 id: ZYS2024-01 briefTitle: Effects of Acupuncture on Abdominal Pain-related Intestinal Flora in Patients With Crohn's Disease overallStatus: COMPLETED date: 2015-03-01 date: 2023-12-31 date: 2024-03-31 date: 2024-04-19 date: 2024-04-19 name: Shanghai Institute of Acupuncture, Moxibustion and Meridian class: OTHER briefSummary: Crohn's disease is an intestinal inflammatory disease, causing abdominal pain, diarrhea and other symptoms. The intestinal flora disorder is closely related to the occurrence and development of Crohn's disease. Acupuncture can induce remission of Crohn's disease during mild to moderate active period, improve clinical symptoms such as abdominal pain. This study is to screen the intestinal bacteria related to abdominal pain in CD, and explore the effects of acupuncture on the intestinal flora related to abdominal pain in CD patients. conditions: Crohn Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 64 type: ACTUAL name: acupuncture name: Sham acupuncture measure: Abdominal pain remission rate measure: Crohn's disease activity index （CDAI） measure: Hospital anxiety and depression scale (HADS) measure: Inflammatory bowel disease questionnaire (IBDQ) measure: Safety evaluation (number of participants with abnormal routine blood tests) measure: Safety evaluation (number of participants with abnormal Liver function tests) measure: Safety evaluation (number of participants with abnormal Renal function tests) measure: Gut microbiota composition structure and function measure: Correlation between changes in relative abundance of gut microbes and abdominal pain sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Institute of Acupuncture, Moxibustion and Meridian city: Shanghai zip: 200000 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06375369 id: Pro00127121 briefTitle: Digital Health Pathway for Children With Medical Complexity Requiring Tracheostomy acronym: DECIDE-T overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2025-12-31 date: 2025-12-31 date: 2024-04-19 date: 2024-04-23 name: University of Alberta class: OTHER name: Alberta Innovates Health Solutions briefSummary: The DECIDE-T project is developing a standardized clinical pathway specifically for pediatric patients who require tracheostomy with or without long-term ventilation (tracheostomy/LTV). These patients represent a small portion of Alberta's population but account for over 50% of pediatric patients hospitalized for more than 180 days. The pathway will include a hospital-to-home directive that incorporates digital health solutions to provide support to families, caregivers, and healthcare professionals. Digital supports will include a Connect Care pathway, resources for informed decision-making, educational modules, high-fidelity simulations for family and caregiver education, an online parental resource center, and access to peer support within the hospital and community, as well as a post-discharge telehealth program.